211-225 of 308
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Sara Lonardi, MD
Aparna R. Parikh, MD
Alan Venook, MD
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Susana Campos, MD, MPH
Nicoletta Colombo, MD
Ritu Salani, MD, MBA
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
- advertisement
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD
Wenxin Xu, MD
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
- advertisement
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Ignacio Duran, MD
Wenxin Xu, MD
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Susana Campos, MD, MPH
Ritu Salani, MD, MBA
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Nicoletta Colombo, MD
Susana Campos, MD, MPH
